Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PK101
- Development stage
- Unknown
- Lead developer
- Pionex Management Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**PK101** is an oral fixed-dose combination of celecoxib and PG201, a 12-herb ethanol soft extract used for osteoarthritis. The product contains 100 mg celecoxib and 405.4 mg PG201 per tablet. Celecoxib selectively inhibits cyclooxygenase-2 to reduce inflammatory prostaglandin production, while PG201 has been reported to suppress inflammatory cytokine pathways including interleukin-1 beta and tumor necrosis factor alpha. PK101 was developed by PMG Pharm for symptomatic knee osteoarthritis, evaluated in Phase 3, and subsequently marketed in South Korea as Layla DS. ([cnu.elsevierpure.com](https://cnu.elsevierpure.com/en/publications/comparison-of-a-fixed-dose-combination-of-celecoxibpg201-laylasup/))
- Brand names
- Layla DS
- Other names
- celecoxib + PG201celecoxib/PG201
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)IL1B (Interleukin-1 beta)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on PK101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PK101.